Clinical Trials on Antepartum Hemorrhage in Germany

Total 765 results

OHB Neonatology Ltd.

Recruiting

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

Intraventricular Hemorrhage | Bronchopulmonary Dysplasia | Chronic Lung Disease of Prematurity | Retinopathy of Prematurity (ROP)

Finland, United States, France, Italy, United Kingdom, Germany, Canada, Ireland, Japan, Netherlands, Portugal, Spain, Sweden
CSL Behring

Completed

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

Hemophilia B

Germany, Australia, Italy, Israel, Czech Republic, Spain, France, Canada, Austria, Russian Federation
Celgene

Active, not recruiting

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States, Italy, Canada, France, Germany, Netherlands, Spain
Hoffmann-La Roche

Completed

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Spain, Denmark, Netherlands, Sweden, Poland, France, Germany, Czechia, Norway
Janssen-Cilag G.m.b.H

Completed

A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma

Multiple Myeloma

Germany
Novo Nordisk A/S

Completed

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B (paradigm™7)

Congenital Bleeding Disorder | Haemophilia B

United States, Switzerland, Germany
ECRI bv
University of Bern; European Cardiovascular Research Center; Terumo Medical Corporation and other collaborators

Completed

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen (MASTER DAPT)

Coronary Artery Disease | PCI | High Bleeding Risk

Netherlands, France, United Kingdom, Australia, Singapore, Japan, Italy, Poland, Spain, Switzerland, Israel, Argentina, Austria, Bahrain, Bangladesh, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, India, Korea, Republic... and more
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS)

Multiple Myeloma

Austria, Greece, Italy, Netherlands, Germany
Regeneron Pharmaceuticals

Recruiting

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy (Honey-B)

Hemophilia B

United States, Germany, United Kingdom, Canada
AstraZeneca

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, Germany, China, Japan
Novartis Pharmaceuticals

Completed

Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

Multiple Myeloma

Germany, Italy, Spain, Canada, United States, Australia
Baxalta now part of Shire

Completed

ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)

Hemophilia A | Congenital Factor VIII (FVIII) Deficiency

United Kingdom, France, Germany, Hungary
Janssen Research & Development, LLC

Recruiting

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (TRIMM-3)

Relapsed/ Refractory Multiple Myeloma

United States, Germany, Spain, France
Stichting European Myeloma Network
Fondazione EMN Italy Onlus

Completed

COVID-19 Infection and Multiple Myeloma (EMN-COVID)

Covid19 | Multiple Myeloma | Corona Virus Infection

Czechia, Netherlands, United Kingdom, Belgium, Germany, Austria, Greece, Italy
Janssen-Cilag G.m.b.H

Completed

Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma

Multiple Myeloma

Germany
Novartis Pharmaceuticals

Completed

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

Germany, United States, France
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Acquired Hemophilia A

United States, Italy, United Kingdom, Germany, Austria, Netherlands, France
Wuerzburg University Hospital
Celgene Corporation; ClinAssess GmbH

Active, not recruiting

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Previously Untreated Symptomatic Multiple Myeloma

Germany
Janssen-Cilag G.m.b.H

Completed

Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma

Multiple Myeloma

Germany
Novo Nordisk A/S

Enrolling by invitation

A Study Following Males With Haemophilia A on Prophylaxis With Esperoct® (pathfinder9)

Haemophilia A

Austria, Spain, Bulgaria, Croatia, Estonia, Hungary, Italy, Lithuania, Portugal, Greece, Germany, Czechia, Slovenia, Switzerland, Slovakia
Novartis Pharmaceuticals

Completed

Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma

Italy, Australia, Germany, Spain, France, Japan, United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Terminated

BAX 802 in CHA With Inhibitors (CHAWI)

Hemophilia A

Netherlands, Spain, Italy, Turkey, Bulgaria, United States, Canada, Germany, Norway, Poland, Russian Federation, South Africa
Pharmacyclics Switzerland GmbH
Janssen Research & Development, LLC

Completed

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Spain, Germany, Turkey, Greece, Italy, Czechia
Bayer

Active, not recruiting

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A (HEM-POWR)

Hemophilia A

Canada, Japan, Spain, United States, Germany, Sweden, Belgium, Brazil, Greece, Italy, Netherlands, Taiwan, Denmark, Kuwait, Saudi Arabia, United Arab Emirates, Norway, Colombia, Switzerland, Slovenia
Kiadis Pharma

Terminated

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Lymphoma | Myeloid Leukemia | Myeloproliferative Disorders | Multiple Myeloma | Myelodysplastic Syndrome | Lymphoblastic Leukemia

Canada, Netherlands, Germany, Belgium, United States, Italy, United Kingdom
Travere Therapeutics, Inc.

Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (EPPIK)

Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy | Minimal Change Disease | Alport Syndrome | IgA Vasculitis

United States, Italy, Netherlands, Poland, Spain, United Kingdom, Germany, Sweden
CSL Behring

Completed

Quality of Life Study of Helixate NexGen

Hemophilia A

Austria, Belgium, France, Germany, Italy, Spain, Switzerland
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Multiple Myeloma

United Kingdom, Czechia, Australia, Austria, Belgium, Denmark, Germany, Greece, Italy, Netherlands, Norway, Serbia, Switzerland, Turkey, Brazil
Novo Nordisk A/S

Completed

Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery

Acquired Bleeding Disorder | Cardiac Surgery Requiring Cardiopulmonary Bypass

United States, Israel, Germany, Canada, Sweden, United Kingdom, Spain, Italy, Denmark, Japan
Baxalta now part of Shire

Completed

BAX 826 Dose-Escalation Safety Study

Hemophilia A

Spain, Bulgaria, Germany, United Kingdom, Italy, Poland, Russian Federation, Netherlands, Hungary
Bayer

Completed

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis (TAURUS)

Hemophilia A, Congenital

Slovenia, Italy, Germany, France, United States, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan
Novo Nordisk A/S

Completed

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A (pathfinder™7)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Germany, France, Denmark
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Hemophilia A

United States, France, Austria, United Kingdom, Germany, Belgium, Canada, Italy, Sweden
Molecular Partners AG

Completed

A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma

Multiple Myeloma in Relapse

Poland, Italy, Germany, Denmark, Czechia, Austria
Oncopeptides AB

Terminated

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma (LIGHTHOUSE)

Relapsed Multiple Myeloma | Relapsed-Refractory Multiple Myeloma

Serbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
Celgene

Recruiting

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

Multiple Myeloma

United States, France, Germany, Spain, United Kingdom, Italy
Novo Nordisk A/S

Enrolling by invitation

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

Haemophilia B

Canada, United Kingdom, Czechia, Germany, Greece, Austria, Belgium, Croatia, Denmark, Finland, Norway, Portugal
Swedish Orphan Biovitrum
Syneos Health

Active, not recruiting

A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa (FREEDOM)

Hemophilia A, Severe

Germany, Spain, France, Czechia, Netherlands, Ireland, Austria, Croatia, Greece, Italy, Norway, Slovenia, Sweden, United Kingdom
Celgene

Completed

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)

Multiple Myeloma

United States, Canada, Belgium, France, Germany, Italy, Japan, Spain
European Myeloma Network
Janssen Research & Development, LLC

Active, not recruiting

Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone (EMN14)

Multiple Myeloma

Netherlands, Belgium, Germany, Spain, Czechia, Greece, Italy, Denmark, Serbia, Turkey
Hoffmann-La Roche
Roche Pharma AG

Terminated

Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma (COMPARE)

Multiple Myeloma

Germany
Baxalta now part of Shire

Active, not recruiting

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Hemophilia A

Spain, Thailand, Hungary, Taiwan, Korea, Republic of, Czechia, Germany, Sweden, Italy, Croatia, United States, Bulgaria, Netherlands
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States, Spain, Poland, Italy, Germany, France, Switzerland, Austria, Japan, United Kingdom
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Japan, Israel, Austria, Bulgaria, France, Germany, Italy, Russian Federation, Spain
RWTH Aachen University
Novartis Pharmaceuticals

Active, not recruiting

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia (Ruxo-BEAT)

Polycythemia Vera (PV) | Essential Thrombocythemia (ET)

Germany
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN 2)

Hemophilia A

United States, France, Germany, Italy, South Africa, Spain, Turkey, Japan, United Kingdom, Costa Rica
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma

Multiple Myeloma

France, Belgium, Germany, Spain, Portugal, Greece, Austria, Luxembourg
Hoffmann-La Roche

Recruiting

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, Denmark, Spain, Australia, Italy, New Zealand, France, Canada, Germany
Celgene Corporation

Completed

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Germany
Celgene

Completed

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Multiple Myeloma

Austria, Italy, France, Spain, Netherlands, Germany, Greece, United Kingdom

Clinical Trials on Antepartum Hemorrhage in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations